Search | Clinical Trials Finder

Conditions: Pneumococcal Infection
Interventions: 23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine; Biological
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 50 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: San Francisco, California • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: HIV Infections, Cytopenias
Interventions: Zidovudine, Sargramostim; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
Interventions: Rituximab, Filgrastim, EPOCH; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C Virus, Hiv Infections
Interventions: bavituximab; Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more

Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, AIDS Virus, Human Immunodeficiency Virus, Human Immunodeficiency Viruses
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Pneumococcal Infections
Interventions: 13-valent pneumococcal conjugate vaccine, Blood draw; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: HIV-1-infection
Interventions: Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch; Drug
Lead sponsor: Quest Clinical Research; Other
Eligibility: 45 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: VH3810109, Fostemsavir (FTR), SOC INSTI-based ART; Biological · Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Bakersfield, California • San Diego, California • Ft. Pierce, Florida + 9 more

Conditions: HIV, HIV Infections, Pregnancy
Interventions: Darunavir, Ritonavir, Etravirine, Rilpivirine, Darunavir/Cobicistat (FDC); Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 16
States / cities: Daytona Beach, Florida • Jacksonville, Florida • Miami, Florida + 13 more

Conditions: HIV (Human Immunodeficiency Virus)
Interventions: predictive emergency room alerts (pERA), Standard of care; Other
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years and older
Enrollment: 2,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: CD4-IgG, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Diego, California • Miami, Florida • Worcester, Massachusetts

Conditions: HIV, HIV Infections
Interventions: Energex HemoModulator; Device
Lead sponsor: Energex Systems, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: HIV Infections, Syphilis
Interventions: Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: Sarcoma
Interventions: thalidomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV I Infection
Interventions: Estradiol; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 11 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 18 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 33
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 21 more

Conditions: HIV (Human Immunodeficiency Virus)
Interventions: Conventional Smell Training Group, Scented Marker Group; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV Infection, Acquired Immunodeficiency Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Toxoplasmosis, Cerebral, HIV Infections
Interventions: Pyrimethamine, Leucovorin calcium, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Hiv
Interventions: Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • San Antonio, Texas + 1 more

Conditions: HIV Infections, Neurologic Disorders
Interventions: Anakinra; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 61 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: Human Immunodeficiency Virus
Interventions: PATH; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Ysidro, California

Conditions: HIV-1-infection
Interventions: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Pneumonia Vaccine in Aging HIV Positive Individuals

A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)

A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Evaluating an Algorithm-Based Implementation Strategy to Improve HIV Care Outcomes

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

Safety Study of the HemoModulator System for the Treatment of Patients With Human Immunodeficiency Virus (HIV)

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)

Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

Boosting Olfactory and Sensory Training Study (BOOST)

Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients

A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection

Peers Plus Mobile App for Treatment in HIV

Bictegravir in the Elderly Living With HIV (BICEP)